Sunday, November 29, 2020 8:36:24 PM
Kyungdong Pharmaceutical acquires permission to export raw materials for COVID-19 treatment 'surge'
[Asia Times = Reporter Kim Ji-ho] The news of the export license of 'Bushiramin', which is being developed overseas as a treatment for Corona 19, is on the rise by Kyungdong Pharmaceutical.
As of 9:34 am on the 30th, Kyungdong Pharmaceutical is recording 13,150 won, a 21.20% increase from the previous trading day.
According to industry sources, Kyungdong Pharmaceutical received a permit for export of bushramin raw materials from the Ministry of Food and Drug Safety on the 26th.
Bushramin is a treatment for rheumatoid arthritis, recently approved by the US Food and Drug Administration (FDA) for a phase 3 clinical trial by Canadian pharmaceutical company Revive Therapeutics to develop it as a treatment for COVID-19.
Like remdesivir, bushramin is expected to re-create a drug for the treatment of Corona 19.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM